What question did this study set out to answer?

April 24, 2026Open Access

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea

Key Points

To evaluate the efficacy and safety of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B.
Conducted a multicenter randomized trial in Korea.
Compared virologic, biochemical, and serologic outcomes between entecavir and tenofovir alafenamide.
Evaluated safety profiles of both treatments.
Switching to tenofovir alafenamide maintained virologic suppression similar to continuing with entecavir.
Biochemical and serologic outcomes were comparable between the two treatments.
Safety profiles showed no significant differences.

Abstract

Switching from ETV to TAF was noninferior to continuing ETV in maintaining virologic suppression, with comparable biochemical, serologic, and safety outcomes. (ClinicalTrials. gov identifier NCT06000657).

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Shin et al. (Wed,) studied this question.

synapsesocial.com/papers/69eb0a2e553a5433e34b453a https://doi.org/https://doi.org/10.5009/gnl250479

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper